$CBIS IRVINE, CA--(Marketwired - Nov 3, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announces that its in-house lab is almost complete and has commenced clinical development plans to begin working with its partner IGXBio, Inc. to develop effective cannabinoid therapeutics using IGXBio's Immunotherapy (GenePro®, also referred to as Δ4SHIVKU2) FDA Investigational New Drug (IND) Number 015982.

http://www.marketwired.com/press-release/cann...172654.htm

$GRCU $GRNH $CGRW $CANN $CBIS $GRWC $TRTC $MJNA